iXpressGenes
iXpressGenes is a biotechnology company dedicated to transforming trauma care through innovative, science-driven solutions. Their mission is to bridge the gap between mental and physical health by detecting and addressing trauma-induced conditions before symptoms emerge. Leveraging advanced RNA biomarker technology, iXpressGenes empowers healthcare providers to deliver proactive, data-driven care that prevents long-term suffering and improves patient outcomes. The company is committed to early detection, prevention, and the development of tools that legitimize the biological realities of trauma, ultimately redefining the future of trauma care.
iXpressGenes
601 Genome Way NW Suite 2023, Huntsville, AL 35806
iXpressGenes is currently seeking investment
iXpressGenes is seeking a series-a investment in the range of 1m-5m
What We Do
A simple blood test that identifies autoimmune indicators and genetic biomarkers of trauma-induced diseases, including PTSD, before symptoms develop. The test supports early intervention and personalized treatment planning.
A novel reagent engineered for COVID-19 and other pathogen detection, developed by iXpressGenes scientists at the HudsonAlpha Institute for Biotechnology.
A rare environmental DNA library created from extremophilic samples (hot springs, thermal vents, permafrost) to support the development of novel antibiotics.
A free, two-week educational program introducing the basics of cloud analytics.
A cutting-edge blood test using advanced RNA biomarker technology to detect immune and neuro-inflammatory responses linked to PTSD and trauma-induced diseases. The test provides objective, non-invasive assessment of PTSD risk and enables early intervention before symptoms appear.
Comprehensive resources and expert-led training for healthcare providers to master trauma-focused care, integrate TAI™ screening into clinical workflows, and enhance patient outcomes.
Psychological and Cognitive Health and Performance
Show More (2)Digital Health Technologies
Show More (1)Key People
News & Updates
iXpressGenes was awarded a $1 million Department of Defense contract to develop novel antibiotics from extremophilic microbiomes.
iXpressGenes is supported by the startup accelerator Gener8tor.
iXG has developed a first-of-its-kind blood test to detect trauma-related inflammation, marking a major step forward in PTSD screening and early intervention.
Nonprofit Kids to Love and iXpressGenes launched a groundbreaking PTSD clinical trial combining therapy with a blood-based inflammation test—believed to be the first of its kind in the nation.
Kids to Love is partnering with iXpressGenes in a new clinical trial aimed at addressing PTSD through bloodwork and therapy.
WellStone, the largest mental health provider in North Alabama, has ordered several hundred Trauma Autoimmune Indicator tests from iXpressGenes to enhance trauma screening.